Download PDF
Arzneimittelforschung 2010; 60(11): 667-674
DOI: 10.1055/s-0031-1296345
Analgesics · Anti-inflammatories · Antiphlogistics · Antirheumatic Drugs
Editio Cantor Verlag Aulendorf (Germany)

Species difference in the in vitro and in vivo metabolism of amtolmetin guacil

Kishore Kumar Hotha
1   Bioanalytical Department, Integrated Product Development, Dr. Reddy’s Laboratories Ltd, Bachupalli, Hyderabad, India
2   Department of Chemistry, JNT University, Anantapur, India
,
Vijaya Bharathi Dasari
1   Bioanalytical Department, Integrated Product Development, Dr. Reddy’s Laboratories Ltd, Bachupalli, Hyderabad, India
,
Abdul Naveed Shaik
3   Discovery Research, Dr. Reddy’s Laboratories Ltd, Miyapur, Hyderabad, India
,
Muzeeb Syed
3   Discovery Research, Dr. Reddy’s Laboratories Ltd, Miyapur, Hyderabad, India
,
Vittal Shivva
3   Discovery Research, Dr. Reddy’s Laboratories Ltd, Miyapur, Hyderabad, India
,
Ravindranath Krishnarao Lakshmanarao
4   Department of Chemistry, SK University, Anantapur, India
,
Jayaveera Narasimhulu Korlakunta
2   Department of Chemistry, JNT University, Anantapur, India
,
Ramesh Mullangi
1   Bioanalytical Department, Integrated Product Development, Dr. Reddy’s Laboratories Ltd, Bachupalli, Hyderabad, India
› Author Affiliations
Further Information

Publication History

Publication Date:
30 December 2011 (online)

    Permissions and Reprints

Abstract

Tolmetin (TMT, CAS 26171-23-3) is a non-steroidal anti-inflammatory drug (NSAID) indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and juvenile rheumatoid arthritis. As TMT causes gastro-intestinal side effects like other NSAIDs, its non-acidic prodrug amtolmetin guacil (AMG, CAS 87344-06-7) was synthesized. AMG has similar NSAID properties like TMT with additional gastroprotective property. The aim of this study was to investigate whether TMT and AMG are differentially metabolised in rat and human plasma (fresh and acidified) and liver microsomes. TMT was found to be stable in all the matrices tested viz., rat and human plasma (fresh and acidified) and liver microsomes. AMG was found to be stable only in acidified rat and human plasma. On the contrary, in fresh human plasma and human liver microsomes AMG was rapidly converted to two metabolites, which were subsequently identified as MED5 and MED5 methyl ester, without yielding any intact TMT. However, in rat fresh plasma and liver microsomes, AMG formed MED5 (predominant) and TMT. To corroborate the in vitro findings, in vivo pharmacokinetics (PK) studies were done following separate dosing of AMG in both rats and humans. In rats, the PK data substantiated that following oral administration of AMG it will be converted to TMT resulting in similar PK parameters observed for TMT when it was administered alone. In humans, however, AMG yields low levels of TMT which substantes the in vitro results. Levels of AMG were not detectable in the plasma. These results confirm the species differences in the in vitro and in vivo metabolism and disposition of AMG. More research work to further explore and understand AMG metabolism in humans is required.

Key words

Amtolmetin guacil, humans, metabolism, pharmacokinetics, rats - CAS 26171-23-3 - CAS 87344-06-7 - Non-steroidal anti-inflammatory drugs - Tolmetin
 

  • References

  • 1 Allinger N. Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms. J Am Chem Soc. 1977; 99: 8127-34
    CrossrefPubMedSearch in Google Scholar
  • 2 Burkert U, Allinger N In: Molecular mechanics. ACS Monograph. 99. Washington (DC): American Chemical Society; 1982
    Search in Google Scholar
  • 3 Pisano C, Grandi D, Morini G, Coppelli G, Vesci L, Lo Giudice P et al. Gastrosparing effect of new anti-inflammatory drug amtolmetin guacyl in the rat: involvement of nitric oxide. Dig Dis Sci. 1999; 44: 713-24
    CrossrefPubMedSearch in Google Scholar
  • 4 Tubaro E, Belogi L, Mezzadri CM, Bettelli E. Impact on the bowel of amtolmetin guacyl, a new gastroprotective nonsteroidal anti-inflammatory drug. Eur J Pharmacol. 2003; 467: 173-83
    CrossrefPubMedSearch in Google Scholar
  • 5 Riezzo G, Chiloiro M, Montanaro S. Protective effects of amtolmetin guacyl verus placebo diclofenac and misoprostol in healthy volunteers evaluated as gastric electric activity in alcohol-induced stomach damage. Dig Dis Sci. 2001; 46: 1797-804
    CrossrefPubMedSearch in Google Scholar
  • 6 Tubaro E, Belogi L, Mezzadri CM, Ruco L, Stoppacciaro A. Studies on the gastric tolerability of the new nonsteroidal anti-inflammatory drug amtolmetin guacyl. Arzneimittelforschung. 1995; 45: 1298-302
    PubMedSearch in Google Scholar
  • 7 Coruzzi G, Bertaccini G. Gastric effects of the novel antisteroidal anti-inflammatory drug amtolmetin guacyl. Nutrition. 1999; 15: 325-6
    CrossrefPubMedSearch in Google Scholar
  • 8 Ghirardini M, Betelemme L, Fatti F, Bonollo L, Martini A. Evaluation of the gastric tolerability of MED 15 in comparison with indomethacin: double blind study in healthy volunteers. Drugs Exp Clin Res. 1990; 26 Suppl: 19-24
    PubMedSearch in Google Scholar
  • 9 Petazzi I, Corberi G, Bonollo L, Martini A. Clinical study of the therapeutic activity and of the tolerability of Artromed in comparison with naproxen in patients with osteoarthritis in different localizations. Drugs Expl Clin Res. 1990; 26 Suppl: 25-30
    PubMedSearch in Google Scholar
  • 10 Nappi C, Nolfe G, La Pinta M, Colace G, Ruotolo C, Affinito P. The treatment of postoperative pain in obstetrical-gynecologic surgery. A comparative study between ST-679 and paracetamol. Clin Ter. 1993; 142: 47-52
    PubMedSearch in Google Scholar
  • 11 Lingetti M, Ciarimboli M, Porfido FA, Imparato L, Sorrentino GP, Garzya G et al. An evaluation of the therapeutic activity and tolerance of ST-679 in patients with osteroarthiritis at different sites: a controlled double-blind study vs. tolmetin. Clin Ter. 1993; 142: 29-40
    PubMedSearch in Google Scholar
  • 12 Meloni P, Demuro G, Cara L, Garau D, Uras G, Suddu L. Evaluation of the effectiveness and tolerability of MED 15 vs piroxicam in patients with acute epicondylitis. Clin Ter. 1995; 146: 453-6
    PubMedSearch in Google Scholar
  • 13 Bianchi Porro G, Montrone F, Lazzaroni M, Manzionna G, Caruso I. Clinical and gastroscopic evaluation of amtolmetin guacyl versus diclofenac in patients with rheumatoid arthritis. Ital J Gastroenterol Hepatol. 1999; 31: 378-85
    PubMedSearch in Google Scholar
  • 14 Tubaro E, Belogi L, Mezzadri CM. The mechanism of action of amtolmetin guacyl, a new gastroprotective nonsteroidal anti-inflammatory drug. Eur J Pharmacol. 2000; 387: 233-44
    CrossrefPubMedSearch in Google Scholar
  • 15 Li YH, Li J, Huang Y, Lu XW, Jin Y. Gastroprotective effect and mechanism of amtolmetin guacyl in mice. World J Gastroenterol. 2004; 10: 3616-20
    PubMedSearch in Google Scholar
  • 16 Mancinelli A, Bruno G, Cardace G, Morabito E, Marzo A, Arrigoni Martelli E. High-performance liquid chromatographic evaluation of MED 15 and its metabolites MED5 and tolmetin in rat plasma. J Chromatogr. 1991; 553: 81-6
    CrossrefPubMedSearch in Google Scholar
  • 17 Zia-Amirhosseini PZ, Harris RZ, Brodsky FM, Benet LZ. Hypersensitivity to nonsteroidal anti-inflammatory drugs. Nat Med. 1995; 1: 2-4
    PubMedSearch in Google Scholar
  • 18 Chen Q, Doss GA, Tung EC, Liu W, Tang YS, Braun MP et al. Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats. Drug Metab Dispos. 2006; 34: 145-51
    PubMedSearch in Google Scholar
  • 19 Olsen J, Li C, Skonberg C, Bjornsdottir I, Sidenius U, Benet LZ et al. Studies on the metabolism of tolmetin to the chemically reactive acyl-coenzyme A thioester intermediate in rats. Drug Metab Dispos. 2007; 35: 758-64
    CrossrefPubMedSearch in Google Scholar
  • 20 Olsen J, Bjornsdottir I, Honore Hansen S. Identification of coenzyme A-related tolmetin metabolites in rats: relationship with reactive drug metabolites. Xenobiotica. 2003; 33: 561-70
    CrossrefPubMedSearch in Google Scholar
  • 21 Ding A, Ojingwa JC, McDonagh AF, Burlingame AL, Benet LZ. Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry. Proc Natl Acad Sci USA. 1993; 90: 3797-801
    CrossrefPubMedSearch in Google Scholar
  • 22 Ding A, Zia-Amirhosseini P, McDonagh AF, Burlingame AL, Benet LZ. Reactivity of tolmetin glucuronide with human serum albumin. Identification of binding sites and mechanisms of reaction by tandem mass spectrometry. Drug Metab Dispos. 1995; 23: 369-76
    PubMedSearch in Google Scholar
  • 23 Rao MN, Biju B, Ansar AK, Mujeeb S, Ramesh M, Srinivas NR. “Open access” generic method for continuous determination of major human CYP450 probe substrates/metabolites and its application in drug metabolism studies. Xenobiotica. 2003; 33: 1233-45
    CrossrefPubMedSearch in Google Scholar
  • 24 Hotha KK, Bharathi DV, Kumar SS, Reddy YN, Chatki P, Ravindranath LK et al. A highly sensitive LC-MS/MS method for quantitation of tolmetin and MED-5 in human plasma: Application to a clinical pharmacokinetic study. Biomed Chromatogr . Forthcoming 2010
    PubMedSearch in Google Scholar
  • 25 Grindel JM. The pharmacokinetic and metabolic profile of the anti-inflammatory agent tolmetin in laboratory animals and man. Drug Metab Rev. 1981; 12: 363-77
    CrossrefPubMedSearch in Google Scholar
  • 26 Migdalof BH, Yorgey KA, Popkave CG. The time course of tolmetin and its metabolites in the plasma of individual rats and mice. Drug Metab Dispos. 1976; 4: 468-73
    PubMedSearch in Google Scholar
  • 27 RxList. The Internet Drug Index [Internet]. RxList Inc.; c2010 [cited 2010 Feb 5]. Tolectin. Available from: http://www.rxlist.com/tolectin-drug.htm.
    PubMed
  • 28 Hyneck ML, Smith PC, Unseld E, Benet LZ. High-performance liquid chromatographic determination of tolmetin, tolmetin glucuronide and its isomeric conjugates in plasma and urine. J Chromatogr. 1987; 420: 349-56
    CrossrefPubMedSearch in Google Scholar